466 related articles for article (PubMed ID: 19741722)
21. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M
Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
[TBL] [Abstract][Full Text] [Related]
22. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Laubach JP; Mitsiades CS; Roccaro AM; Ghobrial IM; Anderson KC; Richardson PG
Leuk Lymphoma; 2009 May; 50(5):694-702. PubMed ID: 19452315
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib: a review of its use in patients with multiple myeloma.
Curran MP; McKeage K
Drugs; 2009; 69(7):859-88. PubMed ID: 19441872
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
26. [Proteasome inhibitors in treatment of multiple myeloma].
Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
[TBL] [Abstract][Full Text] [Related]
27. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG; Mitsiades C; Ghobrial I; Anderson K
Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
[TBL] [Abstract][Full Text] [Related]
28. First proteasome inhibitor approved for multiple myeloma.
Twombly R
J Natl Cancer Inst; 2003 Jun; 95(12):845. PubMed ID: 12813164
[No Abstract] [Full Text] [Related]
29. Carfilzomib: a novel second-generation proteasome inhibitor.
Khan ML; Stewart AK
Future Oncol; 2011 May; 7(5):607-12. PubMed ID: 21568676
[TBL] [Abstract][Full Text] [Related]
30. Current status of bortezomib in the treatment of multiple myeloma.
Cavo M
Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
[TBL] [Abstract][Full Text] [Related]
31. Clinical update: novel targets in multiple myeloma.
Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Laura R; Cibeira MT; Uriburu C; Yantorno S; Salamero O; Bladé J; Montserrat E
Eur J Haematol; 2006 May; 76(5):405-8. PubMed ID: 16529604
[TBL] [Abstract][Full Text] [Related]
33. The ubiquitin proteasome pathway from bench to bedside.
Orlowski RZ
Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Hideshima T; Richardson PG; Anderson KC
Mol Cancer Ther; 2011 Nov; 10(11):2034-42. PubMed ID: 22072815
[TBL] [Abstract][Full Text] [Related]
35. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
36. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibitors in multiple myeloma: 10 years later.
Moreau P; Richardson PG; Cavo M; Orlowski RZ; San Miguel JF; Palumbo A; Harousseau JL
Blood; 2012 Aug; 120(5):947-59. PubMed ID: 22645181
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
39. Targeting the proteasome pathway.
Tsukamoto S; Yokosawa H
Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
[TBL] [Abstract][Full Text] [Related]
40. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]